Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 13/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.65 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.43 |
| ▸ | HNMT | P50135 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9679135 | 0.89 | AHCY (0.80) | AHCYADORA2BADORA3ADORA2A | |
| SCHEMBL14635720 | 0.83 | AHCY (0.71) | AHCYADORA2B | |
| SCHEMBL21057423 | 0.83 | AHCY (0.71) | AHCYADORA2BADORA3ADORA2A | |
| SCHEMBL13524256 | 0.81 | AHCY (0.67) | AHCYADORA2B | |
| SCHEMBL10675784 | 0.81 | AHCY (0.68) | AHCYADORA2BP2RY12 | |
| SCHEMBL10675799 | 0.81 | AHCY (0.68) | AHCYADORA2BP2RY12 | |
| SCHEMBL12149497 | 0.81 | AHCY (0.68) | AHCYADORA2BADORA3ADORA2A | |
| Aristeromycin SCHEMBL10353291 | 0.79 | AHCY (1.00) | AHCYADORA2B | |
| Aristeromycin SCHEMBL7534801 | 0.79 | AHCY (1.00) | AHCYADORA2B | |
| Aristeromycin SCHEMBL10353292 | 0.79 | AHCY (1.00) | AHCYADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371546-A1 | ANTIBODIES TO TICAGRELOR AND METHODS OF USE | MEDIMMUNE LTD (GB) | 2021-12-02 | — | — | US | disclosed |
| US-10954308-B2 | Antibodies to ticagrelor and methods of use | MEDIMMUNE LIMITED (GB) | 2021-03-23 | — | — | US | disclosed |
| US-10487154-B2 | Antibodies to ticagrelor and methods of use | MEDIMMUNE LIMITED (GB) | 2019-11-26 | — | — | US | disclosed |
| US-20190077882-A1 | ANTIBODIES TO TICAGRELOR AND METHODS OF USE | MEDIMMUNE LIMITED (GB) | 2019-03-14 | — | — | US | disclosed |
| US-9982061-B2 | Antibodies to ticagrelor and methods of use | MEDIMMUNE LIMITED (GB) | 2018-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077882-A1 | ANTIBODIES TO TICAGRELOR AND METHODS OF USE | NT5C2, GP6, P2RY6 | AHCY 213/4885ADORA2B 12/4885P2RY12 9/4885 |
| US-10954308-B2 | Antibodies to ticagrelor and methods of use | NT5C2, GP6, P2RY6 | AHCY 213/4885ADORA2B 12/4885P2RY12 9/4885 |
| US-20210371546-A1 | ANTIBODIES TO TICAGRELOR AND METHODS OF USE | NT5C2, GP6, P2RY6 | AHCY 213/4885ADORA2B 12/4885P2RY12 9/4885 |
| US-10487154-B2 | Antibodies to ticagrelor and methods of use | NT5C2, GP6, P2RY6 | AHCY 213/4885ADORA2B 12/4885P2RY12 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.